{
    "organizations": [],
    "uuid": "2cba046f2f3038b4378338cb13e1610056228795",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-bergenbio-favourable-data-reported/brief-bergenbio-favourable-data-reported-across-three-phase-ii-clinical-trials-idUSFWN1PN02A",
    "ord_in_thread": 0,
    "title": "BRIEF-Bergenbio: ‍Favourable Data Reported Across Three Phase II Clinical Trials",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 29 (Reuters) - BERGENBIO ASA:\n* BERGENBIO: ENCOURAGING I-O CLINICAL DATA WITH SELECTIVE AXL INHIBITOR BEMCENTINIB (BGB324) SUPPORTS ITS POTENTIAL AS CORNERSTONE OF CANCER THERAPY\n* ‍FAVOURABLE INTERIM SAFETY DATA REPORTED ACROSS THREE PHASE II CLINICAL TRIALS WITH BEMCENTINIB IN COMBINATION WITH KEYTRUDA​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-29T15:11:00.000+02:00",
    "crawled": "2018-01-30T18:55:55.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "bergenbio",
        "asa",
        "bergenbio",
        "encouraging",
        "clinical",
        "data",
        "selective",
        "axl",
        "inhibitor",
        "bemcentinib",
        "bgb324",
        "support",
        "potential",
        "cornerstone",
        "cancer",
        "therapy",
        "interim",
        "safety",
        "data",
        "reported",
        "across",
        "three",
        "phase",
        "ii",
        "clinical",
        "trial",
        "bemcentinib",
        "combination",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}